Ursula Haak

Statistics

Publications

Citations

673

H-Index

Active since

2004

Affiliations

Helios Klinikum Erfurt(Current)

Ursula Haak is an author at Helios Klinikum Erfurt specializing in lymphoma chemotherapy, rituximab-based therapy, and hematologic malignancy therapy.

Publications per year

2004–2007

Publications

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

Michael Herold, Antje Haas, Stefanie Srock et al. · Journal of Clinical Oncology · 2007 · 504 citations

Medicine, Hematology, Pharmacotherapy +17

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)

Rudolf Weide, H. Köppler, Jochen Heymanns et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2007 · 97 citations

Medicine, Oncology, Pharmacotherapy +14

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

Michael Herold, R. Pasold, Stefanie Srock et al. · Blood · 2004 · 72 citations

Medicine, Oncology, Pharmacotherapy +13

1–3 of 3